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Background: Superparamagnetic poly (lactic-co-glycolic acid) (PLGA)-coated Fe3O4 microcapsules are receiving
increased attention as potential diagnostic and therapeutic modalities in the field of oncology. In this study,
PLGA-coated Fe3O4 microcapsules were combined with a magnetic resonance imaging-guided high-intensity
focused ultrasound (MR-guided HIFU) platform, with the objective of investigating the effects of these composite
microcapsules regarding MR-guided HIFU liver cancer surgery in vivo.
Methods: PLGA-coated Fe3O4 microcapsules consisting of a liquid core and a PLGA-Fe3O4 shell were fabricated
using a modified double emulsion evaporation method. Their acute biosafety was confirmed in vitro using MDA
cells and in vivo using rabbits. To perform MR-guided HIFU surgery, the microcapsules were intravenously injected
into a rabbit liver tumor model before MR-guided HIFU. T2-weighted images and MR signal intensity in normal liver
parenchyma and tumor tissue were acquired before and after injection, to assess the MR imaging ability of the
microcapsules. After MR-guided HIFU ablation tissue temperature mapping, the coagulative volume and
histopathology of the tumor tissue were analyzed to investigate the ablation effects of MR-guided HIFUs.
Results: Scanning and transmission electron microscopy showed that the microcapsules displayed a spherical
morphology and a shell-core structure (mean diameter, 587 nm). The hysteresis curve displayed the typical
superparamagnetic properties of the microcapsules, which are critical to their application in MR-guided HIFU
surgery. In MR-guided HIFU surgery, these microcapsules functioned as an MRI contrast agent, induced significant
hyperthermal enhancement (P < 0.05) and significantly enhanced the volume of coagulative necrosis (P < 0.05).
Conclusions: The administration of PLGA-coated Fe3O4 microcapsules is a potentially synergistic technique
regarding the enhancement of MR-guided HIFU cancer surgery.
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The clinical application of ultrasound is no longer limited
to diagnosis. High-intensity focused ultrasound (HIFU) is
a newly developed technique that applies ultrasonic energy
to a focused region for the hyperthermal treatment of
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unless otherwise stated.chemotherapeutic and radiotherapeutic approaches, HIFU
is a logical and attractive treatment modality that can
selectively and non-invasively destroy multiple foci of
origin [3,4]. Moreover, HIFU provides additional thera-
peutic options in cases where conventional therapies
have failed [5-7].
HIFU performance critically relies on imaging quality
for an accurate determination of tumor location to facili-
tate the optimal deposition of ultrasonic energy in the
tumor. The integration of magnetic resonance imaging. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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offers superior soft tissue MRI resolution combined with
non-invasive real-time tissue temperature mapping (T-
Map) capabilities [8-10]. Consequently, MR-guided HIFU
is being increasingly used in the clinic [11-14]. Despite its
growing clinical acceptance, MR-guided HIFU has two key
limitations. First, MRI as used in MR-guided HIFU can fail
to visualize small early stage or MRI-insensitive tumors
[15-17]. Second, the ultrasonic energy emitted by the MR-
guided HIFU transducer is considerably attenuated when
shifting from an in vitro environment to in vivo tissue; this
attenuation adversely affects MR-guided HIFU ablation ef-
ficiency because the ability of HIFU to successfully ablate
tumors depends on its capacity to deposit energy in tissue
[18-21]. Therefore, limitations in tumor visualization and
in vivo energy deposition adversely affect the treatment ef-
ficacy of MR-guided HIFU.
Superparamagnetic iron-oxide nanoparticles (SPIONs)
possess unique magnetic properties that make them at-
tractive advanced biomaterial candidates [22-25]. In can-
cer diagnosis and therapy, SPIONs can serve as MRI
contrast agents [26,27], miniaturized heaters capable of
destroying malignant cells and colloidal carriers for tar-
geted drug delivery [28-30]. Since SPION-enhanced MR
imaging can be used to monitor the tumor prior to ab-
lation therapy, SPIONs are particularly suitable for MR-
guided HIFU applications. Moreover, as a functional
medium, SPIONs can also change the acoustic tissue
microenvironment in the targeted region, thereby enhan-
cing the tumor-ablative effects of MR-guided HIFUs.
The objective of the present study was to combine the
merits of SPIONs and polymers by constructing a com-
posite particle, namely the superparamagnetic poly (lac-
tic-co-glycolic acid) (PLGA)-coated Fe3O4 microcapsule.
We investigated the in vitro properties of these super-
paramagnetic PLGA-coated Fe3O4 microcapsules and
the in vivo application of these microcapsules in MR-
guided HIFU liver cancer surgery using a rabbit model.
Methods
Synthesis of PLGA-coated Fe3O4 microcapsules
Preparation and storage of the microcapsules were per-
formed in the dark. Briefly, a 200-ml solution (3.1% w/v)
of nano-sized Fe3O4 particles (31 mg/ml; size, 10 nm;
Ocean NanoTech, USA) was added to 2 ml of CH3Cl
dissolved in 100 mg of PLGA (50:50; MW= 20000;
Daigang, China). For cell incubation, the fluorescent dye
DiI was incorporated into the composite microcapsules.
The above mixture was emulsified (Sonics & Materials
Inc., USA) for 45 s. After adding 200 ml of deionized
water, the solution was homogenized (FJ300-SH, Shang-
hai, China) for 5 min with a 10-ml poly(vinyl alcohol)
(PVA; MW= 25000; Sigma) solution (5% w/v). Then, the
CH3Cl solution was removed by mechanical mixing for2 h. The mixture was subsequently centrifuged at
800 rpm for 10 min. After centrifugation, the precipitate
containing large microcapsules was discarded, and the
functionalized PLGA-coated Fe3O4 microcapsules were
generated by a second centrifugation of the remaining
microcapsule suspension at 5000 rpm for 5 min. In
addition, pure PLGA microcapsules were prepared with-
out the addition of Fe3O4 particles and used as a control
agent.
Characterizing PLGA-coated Fe3O4 microcapsules
The average size of the PLGA-coated Fe3O4 microcap-
sules was characterized using the Laser Particle Size
Analyzer System (Zeta SIZER 3000HS: Malvern, PA,
USA). The morphological and structural characteristics
of the microcapsules were estimated using scanning
electron microscopy (SEM) (S-3400 N: Hitachi, Japan)
and transmission electron microscopy (TEM) (H-7500:
Hitachi, Japan). DiI-labeled PLGA microcapsules were
observed using inverted fluorescence microscopy (Olym-
pus IX71: Canada). The magnetic properties of the micro-
capsules were investigated using the Physical Property
Measurement System (PPMS, Model 6000: Quantum
Design).
MDA cell culture and PLGA-coated Fe3O4 microcapsule
uptake by MDA cells
MDA cells obtained from the American Type Culture
Collection (ATCC, USA) were cultured in RPMI-1640
medium supplemented with 10% FBS (both from
Hycline) at 37°C with 5% CO2 in a humidified atmos-
phere and passaged every 2–3 days. DiI-labeled PLGA-
coated Fe3O4 microcapsules were irradiated using a
Co60 gamma ray source for sterilization prior to incuba-
tion with MDA cells.
MDA cells (2 × 105 per well) were placed on six-well
tissue-culture clusters 24 h before incubation with
PLGA-coated Fe3O4 microcapsules. Immediately before
initiating incubation, the medium was removed from
each well and the cells were washed three times with
PBS. They were then incubated with the DiI-labeled
PLGA-coated Fe3O4 microcapsules as described below.
The microcapsules were diluted to a final Fe3O4 concen-
tration of 0.15 mg/ml with culture medium and subse-
quently added to each well. Cells in culture medium
without agents were used as the control group. The cells
with PLGA-coated Fe3O4 were individually cultured for
4, 12 and 24 h, while the control group was cultured for
24 h. Thereafter, the medium was removed from each
well, and the cells were washed three times with PBS
and fixed in 10% formalin solution for 10 min. The cells
were then stained using FITC for 45 min and Hoechst
for 30 min before observation under an inverted fluores-
cence microscope.
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Cell viability was determined using the MTT test. MDA
cells (1 × 104 per well) were seeded into 96-well plates.
After incubation for 24 h, the medium was removed and
replaced with fresh culture medium containing PLGA-
coated Fe3O4 microcapsules at Fe3O4 concentrations of
0.5, 1.0, 2.0, 4.0 and 8.0 mg/ml. Cells in culture medium
without agents were used as the control group. Follow-
ing 24 h incubation, cell viability was measured by the
addition of 20 μl 3-(4,5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT; 5 mg/ml) solution
for 4 h. Then, 150 μl of DMSO was added to dissolve
the formazan crystals. To assess cell viability, optical
density (OD) was measured at 490 nm with an enzyme-
linked immunosorbent assay (ELISA) plate reader.
Acute biosafety of PLGA-coated Fe3O4 microcapsules
Thirty-six New Zealand white rabbits (weight, 2.0–
2.5 kg; age, 2–3 months) were purchased and main-
tained in the Animal Center of Chongqing Medical
University under standard conditions in accordance with
the university’s environmental guidelines. All animal
experiments were approved by the Animal Ethics Com-
mittee of Chongqing Medical University. All animal
experiments and procedures were performed under
complete anesthesia.
Prior to tumor implantation, 18 rabbits were divided
into three groups to determine a safe dosage of PLGA-
coated Fe3O4 microcapsules. Each group received a 2-ml
injection of a different concentration of PLGA-coated
Fe3O4 microcapsules via the ear vein, at Fe3O4 concen-
trations of 1, 4 and 8 mg/ml. Serum was sampled from
the rabbits to detect biochemical indicators of liver, kid-
ney and cardiac function before injection and at 1, 3 and
7 days after injection of the PLGA-coated Fe3O4 micro-
capsules. These biochemical indicators included alanine
aminotransferase (ALT), aspartate aminotransferase (AST),
total bilirubin (TBIL), blood urea nitrogen (BUN), cre-
atinine (SCr), creatine kinase (CK) and lactate dehydro-
genase (LDH).
Animal model and experimental equipment
Rabbits with a VX2 tumor located in the thigh were ob-
tained from the Ultrasound Engineering Institute of
Chongqing Medical University (Chongqing Medical Uni-
versity). The liver tumor model was developed according
to a previously described method [31].
The 18 recipient rabbits with detectable liver cancer
(21 days after VX2 tumor implantation) underwent MR-
guided HIFU treatment using Symphony A Tim 1.5 T
MR-guided HIFU tumor ablation equipment (therapeutic
transducer focal length, 145 mm; diameter, 220 mm;
operating frequency, 0.94 MHz; Chongqing Haifu
Technology, Chongqing, China). This system uses afocused ultrasonic transducer that emits high-intensity
ultrasonic energy to target and destroy the tissue-of-
interest, while the diagnostic MR scanner images the
tumor and monitors the targeted tissue temperature
during the therapeutic process.
MR-guided HIFU surgery for rabbits bearing the VX2 liver
tumor
The 18 recipient rabbits with VX2 liver tumors were
placed on the MR-guided HIFU treatment bed in the
prone position after being completely anesthetized.
Their abdomens were entirely immersed in degassed
water. The rabbits were randomly divided into three
groups: (i) MR-guided HIFU treatment without micro-
capsules (group I; n = 6); (ii) MR-guided HIFU treatment
with a 2-ml intravenous injection of pure PLGA micro-
capsules at a PLGA concentration of 50 mg/ml (group
II; n = 6); and (iii) MR-guided HIFU treatment with a 2-
ml intravenous injection of PLGA-coated Fe3O4 micro-
capsules at a Fe3O4 concentration of 3.1 mg/ml (group
III; n = 6). Prior to MR-guided HIFU ablation, T2-
weighted images were acquired before and at 5 min after
ear vein injection of pure PLGA microcapsules (group
II) and PLGA-coated Fe3O4 microcapsules (group III).
No injection of microcapsules was administered to rab-
bits in group I; thus, in group I, the second image was
acquired at 5 min after the acquisition of the first
image. Additionally, the MR signal intensity (SI) within
the region of interest (including both normal liver par-
enchyma and liver tumor) was measured before and at
2 and 5 min after injection of the various agents to as-
sess the enhanced MR imaging ability. After MR scan-
ning, MR-guided HIFU ablation was performed using
the “ablated-dot” mode, in which each tumor was
destroyed in a single exposure. In all three MR-guided
HIFU groups (groups I, II and III), MR-guided HIFU
ablation parameters were kept constant with a 250-W
acoustic power and a 5-s exposure duration. During
MR-guided HIFU ablation, T-Map was imaged in the
targeted region to investigate the effects of MR-guided
HIFU ablation. To acquire T2-weighted images, turbo
spin echo (TSE) sequences were run at TR values of
4100 ms (TE, 113 ms; FOV, 300 mm × 300 mm; slice
thickness, 4.0 mm).
Animals were sacrificed after MR-guided HIFU abla-
tion, and the livers were immediately removed for
macroscopic observation. The tumor along with the
surrounding normal liver tissue was sectioned into 2-
mm slices, and the maximal section of necrotic tumor
tissue was selected for observation of the area of coagu-
lative necrosis. Then, the length, width and depth of the
necrotic tissue were compiled from each tissue slice to
calculate the volume of coagulative necrosis. The vol-
ume of coagulated tissues in the liver tumor was
Figure 1 The characterization of superparamagnetic PLGA-coated Fe3O4 microcapsules. (A, B) Scanning electron microscope images of
the PLGA-coated Fe3O4 microcapsules at different magnifications. (C) Transmission electron microscope images of the PLGA-coated Fe3O4
microcapsules. (D) Magnetic properties of the superparamagnetic PLGA-coated Fe3O4 microcapsules (M–H magnetization curve).
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W × D (L, length; W, width; D, depth) [32]. In addition,
TEM was performed on the ablated tissue from each
tumor to detect ultrastructural changes in the cancer-
ous tissue.
Statistical analysis
All data are expressed as the mean ± standard deviation.
Various groups were compared for differences using
one-way analysis of variance (one-way ANOVA). AllFigure 2 Morphology of DiI-labeled PLGA-coated Fe3O4 microcapsule
(B) Appearance of microcapsules under fluorescence microscopy. Scale baranalyses were performed using SPSS Statistics 19.0. A
difference with a P-value of <0.05 was deemed statisti-
cally significant.
Results and discussion
Characterization of PLGA-coated Fe3O4 microcapsules
According to the microcapsule size distribution (Additional
file 1), the mean diameter of the prepared PLGA-coated
Fe3O4 microcapsules was 587 ± 60 nm. The characteris-
tic pore cutoff size ranged from 380 to 780 nm and hass. (A) Appearance of microcapsules under light microscopy.
: 10 μm.
Figure 3 Uptake of PLGA-coated Fe3O4 microcapsules by MDA cells observed under fluorescence microscopy. (A) MDA cells after
incubation with DiI-labeled PLGA-coated Fe3O4 microcapsules for 4 h followed by FITC staining for 45 min. The cytoplasm appears green. (B)
MDA cells after staining with Hoechst for 30 min with the nucleus appearing blue. (C) DiI-labeled PLGA-coated Fe3O4 with a red appearance
under fluorescence microscopy. (D) Merged images of (A), (B) and (C). (E) Appearance of microcapsules under light microscopy. (F) MDA cells
after staining with FITC in the absence of PLGA particles. Scale bar: 10 μm.
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some tumors show pore sizes of ≤2 μm [33-35]. In our
study, the smallest particles (approximately 10–20% of
the total particles) in the distribution could enter the
tumor tissue by means of the enhanced permeabilityFigure 4 Cytotoxic effects of PLGA-coated Fe3O4 microcapsules
on MDA cells. Optical density (OD) was measured at 490 nm in
MDA cells incubated with different concentrations of PLGA-coated
Fe3O4 to assess cell viability. The higher the OD, the greater the cell
viability. The OD of MDA cells incubated with PLGA-coated Fe3O4
microcapsules at concentrations of 0.5, 1.0, 2.0, 4.0 and 8.0 mg/ml
were 0.156 ± 0.003, 0.160 ± 0.007, 0.154 ± 0.004 and 0.161 ± 0.007, 0.157
± 0.005, respectively; the OD of the control group was 0.158 ± 0.005.
Results showed no significant differences between the PLGA-coated
Fe3O4 groups and the control group (P> 0.05; MDA cells in culture
medium without agents were used as the control group.and retention (EPR) effect, which allows extravasation
of nanoparticles through large inter-endothelial gaps in
the effective tumor microvasculature for the induction
of the MR signal and HIFU synergistic therapy.
Under SEM imaging, the prepared microcapsules dis-
played a spherical morphology and a non-smooth sur-
face (Figure 1A and B). Because of their organic
solubility and small size, the Fe3O4 nanoparticles embed-
ded themselves in the PLGA shell structure when intro-
duced into the reaction medium prior to the addition of
the PVA molecules in the second emulsion. This struc-
ture was confirmed by TEM imaging (Figure 1C), where
the Fe3O4 nanoparticles were observed on the surface of
the microcapsules as a result of their high electron in-
tensity. The hysteresis curve (Figure 1D) demonstrated
the typical superparamagnetic properties of the PLGA-
coated Fe3O4 microcapsules, which are critical to their
application in MR-guided HIFU surgery.
DiI is a non-cytotoxic lipophilic orange-red fluores-
cent dye that does not affect cell growth and prolifera-
tion. In the preparation process, DiI was miscible with
PLGA and Fe3O4 in chloroform during the formation of
the shell of the composite microcapsules. Using fluores-
cence microscopy, the surface of the microcapsules dis-
played the ring-shaped orange-red fluorescent dye DiI
(Figure 2).
Uptake of PLGA-coated Fe3O4 microcapsules by MDA
cells
To observe the cellular uptake of PLGA-coated Fe3O4 mi-
crocapsules, as well as the impact of these microcapsules
Table 1 Serum biochemical indicators after the injection of PLGA-coated Fe3O4 microcapsules (1 mg/ml)
Pre-injection 1 d 3 d 7 d
ALT (U/L) 64.33 ± 18.34 56.67 ± 15.01 51.00 ± 13.89 54.00 ± 16.09
AST (U/L) 41.33 ± 1.53 42.33 ± 2.52 40.67 ± 4.16 45.33 ± 2.08
TBIL (μmol/L) 3.47 ± 0.40 3.53 ± 0.15 3.27 ± 0.12 3.20 ± 0.26
BUN (mmol/L) 7.55 ± 0.38 8.42 ± 0.39 7.81 ± 0.77 7.50 ± 0.62
SCr (μmol/L) 68.77 ± 7.60 73.70 ± 4.40 62.37 ± 4.10 75.30 ± 9.04
CK (U/L) 3242.67 ± 71.14 3420.00 ± 172.50 3457.67 ± 132.50 3362.33 ± 116.11
LDH (U/L) 839.67 ± 10.02 850.67 ± 19.86 834.00 ± 18.00 857.00 ± 12.77
Note: The same indicators at different time points for pairwise comparisons (P > 0.05 for all of the comparisons).
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labeled PLGA-coated Fe3O4 over different periods of
time. Fluorescence microscopy demonstrated that
PLGA-coated Fe3O4 microcapsules were phagocytosed
by MDA cells (Figure 3), with the number of phagocy-
tosed microcapsules increasing with incubation time
(12 and 24 h). In Figure 3, MDA cells were stained with
FITC and Hoechst for 45 min and 30 min, respectively,
after incubation with DiI-labeled PLGA-coated Fe3O4
microcapsules for 4 h. After staining, the cytoplasm of
the MDA cells appeared green (Figure 3A), the nucleus
appeared blue (Figure 3B), and DiI-labeled PLGA-
coated Fe3O4 appeared red (Figure 3C) under fluores-
cence microscopy. There appear to be green dots in
Figure 3A in the same place as the dots in Figure 3C.
We suspect that these dots were PLGA particles that
were stained by FITC; in addition, we could see the
merged color in the same location (Figure 3D) but we
could not observe these green dots in MDA cells with-
out incubation of the PLGA particles after staining with
FITC (Figure 3F). Thus, we believe that FITC has the
ability to label PLGA particles.
In addition, the OD of MDA cells incubated with
PLGA-coated Fe3O4 at concentrations of 0.5, 1.0, 2.0, 4.0
and 8.0 mg/ml were 0.156 ± 0.003, 0.160 ± 0.007, 0.154 ±
0.004, 0.161 ± 0.007 and 0.157 ± 0.005, respectively; the
OD of the control group was 0.158 ± 0.005. The MTT
assay indicated that the phagocytosed microcapsules hadTable 2 Serum biochemical indicators after the injection of P
Pre-injection 1 d
ALT (U/L) 50.80 ± 14.23 57.17 ± 14
AST (U/L) 43.33 ± 1.56 41.35 ± 2
TBIL (μmol/L) 3.45 ± 0.39 3.54 ± 0.
BUN (mmol/L) 7.79 ± 0.67 8.45 ± 0.
SCr (μmol/L) 66.57 ± 6.70 72.73 ± 4
CK (U/L) 3354.39 ± 96.61 3422.00 ± 1
LDH (U/L) 841.67 ± 11.02 848.63 ± 1
Note: The same indicators at different time points for pairwise comparisons (P > 0.0no significant effect on cell viability relative to the controls
(P > 0.05; Figure 4).
Acute biosafety of PLGA-coated Fe3O4 microcapsules
We injected the PLGA-coated Fe3O4 microcapsules into
rabbits to investigate their acute biosafety in vivo. After
injection of three different concentrations of the micro-
capsules (Fe3O4 concentrations of 1 mg/ml, 4 mg/ml
and 8 mg/ml), there were no obvious abnormalities in
all three groups of rabbits. The serum biochemical indi-
cators (Tables 1, 2 and 3) demonstrated that liver, kidney
and cardiac function in the three groups showed no sig-
nificant changes (P > 0.05) at the different post-injection
time points (1, 3 and 7 days).
PLGA-coated Fe3O4 microcapsules as contrast agents for
MR-guided HIFU surgery
We then investigated the use of PLGA-coated Fe3O4 mi-
crocapsules as contrast agents in MR-guided HIFU abla-
tion. As shown in the T2-weighted images in Figure 5
A1,2, B1,2 and C1,2, PLGA-coated Fe3O4 microcapsules
generated negative contrast enhancement in the liver
(Figure 5C2). Changes in the MR SI of the liver further
demonstrated this effect. As shown in Figure 6, the SIs
of liver parenchyma in the control, PLGA-coated Fe3O4
and PLGA groups before injection, and at 2 and 5 min
after injection were as follows: 928.25 ± 17.41, 908.24 ±
17.38 and 921.04 ± 15.88 (pre-injection); 919.54 ± 18.28,LGA-coated Fe3O4 microcapsules (4 mg/ml)
3 d 7 d
.06 63.53 ± 17.35 53.70 ± 15.11
.46 41.63 ± 3.56 43.83 ± 2.15
17 3.29 ± 0.14 3.21 ± 0.33
37 7.65 ± 0.48 7.66 ± 0.58
.37 64.26 ± 4.11 74.80 ± 8.05
12.53 3446.62 ± 122.30 3277.65 ± 69.40
7.83 823.14 ± 16.73 856.37 ± 13.42
5 for all of the comparisons).
Table 3 Serum biochemical indicators after the injection of PLGA-coated Fe3O4 microcapsules (8 mg/ml)
Pre-injection 1 d 3 d 7 d
ALT (U/L) 59.23 ± 13.77 56.15 ± 14.55 51.30 ± 13.87 61.23 ± 16.55
AST (U/L) 42.88 ± 1.45 41.09 ± 1.65 41.64 ± 2.00 43.56 ± 3.15
TBIL (μmol/L) 3.49 ± 0.38 3.48 ± 0.23 3.37 ± 0.34 3.23 ± 0.32
BUN (mmol/L) 7.58 ± 0.32 8.44 ± 0.43 7.76 ± 0.53 7.59 ± 0.63
SCr (μmol/L) 69.65 ± 5.74 71.88 ± 4.43 66.30 ± 5.31 75.79 ± 7.98
CK (U/L) 3280.98 ± 66.33 3445.09 ± 98.71 3453.98 ± 112.27 3325.0 ± 111.20
LDH (U/L) 853.34 ± 10.71 847.72 ± 15.30 838.99 ± 17.90 850.08 ± 16.98
Note: The same indicators at different time points for pairwise comparisons (P > 0.05 for all of the comparisons).
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16.27, 271.34 ± 15.97 and 917.58 ± 16.47 (5 min), re-
spectively. In addition, the SIs of liver tumors in the
control, PLGA-coated Fe3O4 and PLGA groups before
injection and at 2 and 5 min after injection were as fol-
lows: 921.37 ± 17.91, 918.76 ± 16.88 and 913.64 ± 15.88Figure 5 MR-guided HIFU liver cancer surgery (six rabbits were used
PLGA microcapsules. (C) MR-guided HIFU + PLGA-coated Fe3O4 microcapsu
MR-guided HIFU ablation (the green circle indicates the tumor site). (A2/ B
injection of different agents (the red circle identifies the region that HIFU w
MR-guided HIFU ablation. minT, minimum temperature; avgT, average tem(pre-injection); 924.65 ± 18.28, 783.64 ± 12.53 and 906.25 ±
16.45 (2 min); and 922.44 ± 18.37, 761.53 ± 13.57 and
908.52 ± 14.57 (5 min), respectively. The differences in the
results were analyzed statistically between the groups and
between the time points. Although there were no signifi-
cant changes in SI after the injection of pure PLGA or noin each group). (A) MR-guided HIFU alone. (B) MR-guided HIFU + pure
les. (A1/ B1/C1) T2-weighted images of the targeted tissue before
2/ C2) T2-weighted images of the targeted tissue at 5 min after the
as focused upon). (A3, B3, C3) Tissue temperature mapping during
perature; maxT, maximum temperature.
Figure 6 Analysis of MR signal intensity. The MR signal intensities from T2-weighted images of (A) normal liver parenchyma and (B) tumor
before and after the injection of different agents. The error bars represent the standard deviation.
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tumor at each time point (P > 0.05), the SI was significantly
decreased in the normal liver parenchyma after administra-
tion of the PLGA-coated Fe3O4 microcapsules at 2 and
5 min relative to the other two groups (P < 0.05); however,
the SI was decreased to a significantly lesser degree in the
liver tumor tissue at 2 and 5 min relative to the other two
groups (P < 0.05). These results demonstrated a significant
SI-based imaging contrast between the normal liver paren-
chyma and tumor tissue with the use of PLGA-coated
Fe3O4 microcapsules; this should enhance the imaging cap-
abilities of MR during MR-guided HIFU. We hypothesize
that this differential decrease in SI between the normal liver
parenchyma and tumor tissue may be due to differential
phagocytosis of the microcapsules by liver Kupffer cells;
this is because PLGA-coated Fe3O4 microcapsules have
the ability to distort local magnetic characteristics to
yield a negative enhancement image. This SI-basedFigure 7 Tissue temperature and coagulative volume analysis. (A) Tiss
(B) Volume of coagulative necrosis in the different groups exposed to MR-effect is beneficial for MR-guided HIFU cancer surgery,
because higher-contrast MR images facilitate the accur-
ate localization of ultrasonic energy at the desired
tumor site, resulting in improved therapeutic efficiency
while substantially limiting damage to the surrounding
normal tissue. Therefore, administration of the PLGA-
coated Fe3O4 microcapsules could be used to localize
the tumor using the variation in MR contrast between
different tissues.
PLGA-coated Fe3O4 microcapsules show synergy with MR-
guided HIFU surgery
We also investigated the properties of PLGA-coated
Fe3O4 microcapsules as synergistic agents for MR-
guided HIFU liver cancer surgery. Dibaji et al. assessed
the utility of using magnetic nanoparticles to enhance
heating during HIFU procedures in vitro; their find-
ings demonstrated that the introduction of magneticue temperatures of the different groups after MR-guided HIFU ablation.
guided HIFU. *P < 0.05.
Figure 8 Macroscopic inspection of liver tumors after MR-guided HIFU. (A1/A2) MR-guided HIFU alone. (B1/B2) MR-guided HIFU + pure
PLGA microcapsules. (C1/C2) MR-guided HIFU + PLGA-coated Fe3O4 microcapsules. Black arrows indicate the necrotic tissue in the liver tumors.
Figure 9 Transmission electron microscope images of ablated tumor tissue. (A) MR-guided HIFU alone. The blue arrows indicate the interrupted
cell membranes. (B) MR-guided HIFU + pure PLGA microcapsules. The white arrows indicate the distended mitochondria. (C) MR-guided
HIFU + PLGA-coated Fe3O4 microcapsules. The black arrows indicate the superparamagnetic PLGA-coated Fe3O4 microcapsules.
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In the present study, PLGA-coated Fe3O4 microcapsules
were intravenously administrated via the ear vein into rab-
bits with VX2 liver tumors. The microcapsules penetrated
the liver tumor tissue as a result of the EPR effect and en-
hanced MR-guided HIFU ablation.
During MR-guided HIFU ablation, T-Map provided pre-
cise, real-time evaluation of the therapeutic effect. As
shown in Figure 5 A3, B3 and C3, T-Map provided data on
the extent of thermal ablation in the targeted tissue during
treatment. Reliable thermal feedback from T-Map showed
that the average temperature of the targeted tissue was
raised by >70°C, indicating that the ultrasonic probe
successfully focused a high-energy beam on the tumor tis-
sue, resulting in the induction of coagulative necrosis. In
addition, the average temperature of the ablated region
was significantly higher in the MR-guided HIFU group
using the PLGA-coated Fe3O4 microcapsules compared
with the MR-guided HIFU group using pure PLGA micro-
capsules, or the MR-guided HIFU group without micro-
capsules (Figure 7A; P < 0.05). Moreover, the volume of
coagulative necrosis was substantially larger in the MR-
guided HIFU group with PLGA-coated Fe3O4 microcap-
sules relative to either the MR-guided HIFU group with
pure PLGA microcapsules or the MR-guided HIFU group
without microcapsules (P < 0.05; Figures 7B and 8). Six
TEM images were compared in each group for investiga-
tion of the ultramicrostructure of the targeted tumor tissue
after MR-guided HIFU ablation. The results (Figure 9) re-
garding tumor tissue indicated that: (i) MR-guided HIFU
ablation was evident; (ii) ultrastructural changes were ap-
parent; (iii) mitochondria were severely distended; and (iv)
cell membranes and nuclear membranes were interrupted
and undefined. In the MR-guided HIFU group with
PLGA-coated Fe3O4 microcapsules, the microcapsules
were deposited in the tumor cells, further demonstrat-
ing that they had entered the targeted tumor tissue.
Conclusions
PLGA-coated Fe3O4 microcapsules combine the merits
of the unique magnetic properties of SPIONs and the
excellent biocompatibility of PLGA particles that make
them attractive biomaterial candidates for MR-guided
HIFU cancer ablation. These paramagnetic microcap-
sules exhibited contrast-enhanced imaging capability re-
garding MR imaging after intravenous injection; they
effectively improved the accuracy of MR-guided HIFU
liver cancer surgery. In addition, the introduction of
PLGA-coated Fe3O4 microcapsules enhanced ultrasonic
wave absorption and energy deposition in the targeted
tissue, boosting hyperthermia in the targeted tissue and
improving thermal ablation using MR-guided HIFU in
the focused region. Furthermore, the PLGA-coated Fe3O4
microcapsules exhibited an excellent acute biosafety profileboth in vitro and in vivo. However, the size of the super-
paramagnetic microcapsules used in the current study was
slightly larger than those previously used. This was a limi-
tation of our study and should be addressed in future in-
vestigations. In short, the administration of PLGA-coated
Fe3O4 microcapsules provides an alternative strategy
for MR-guided non-invasive HIFU synergistic therapy
of cancer.
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Additional file 1: Size distribution of the PLGA-coated Fe3O4
microcapsules.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YS prepared the composite microcapsules, performed the animal
experiments and drafted the paper. YYZ participated in the design of the
study and helped to revise the paper. PL evaluated the characteristics of the
microcapsules, DW participated in the MRI-guided HIFU therapy, CCN helped
to carry out the cell experiments, YPG participated in the assessment of the
biosafety of the microcapsules, and RZH contributed to the MTT assay of
cell viability and revision of the manuscript. ZBW helped to carry out the
MRI-guided HIFU liver surgery. ZGW participated in the design of the study,
and in its analysis. HTR designed the study, participated in the data analysis
and helped to revise the paper. All authors read and approved the final
manuscript.
Acknowledgments
This work was partly supported by the National Nature Science of China
(Grant Numbers 81471713, 81371579, 81401423 and 81161120548), the
National Research Program of China (973 Program, Grant Number
2011CB707905) and Chongqing University Innovation Team Plans
(KJTD201303). The authors are grateful to Yang Zhou, Ph.D., and Hongxia
Shen for their assistance with the animal experiments. We also thank Wei
Wu, Yingjiang Liu, Qi Wang and Chongyan Li for their support and technical
expertise.
Author details
1Second Affiliated Hospital, Institute of Ultrasound Imaging, Chongqing
Medical University, Chongqing, P. R. China. 2College of Biomedical
Engineering, Chongqing Medical University, Chongqing, P. R. China.
Received: 11 April 2014 Accepted: 24 October 2014
Published: 3 November 2014
References
1. Santoro RR, Sommersguter GF: Actual state of ultrasonic therapy. Prensa
Med Argent 1950, 37:2855–2864.
2. Vaezy S, Andrew M, Kaczkowski P, Crum L: Image-guided acoustic therapy.
Annu Rev Biomed Eng 2001, 3:375–390.
3. Sibille A, Prat F, Chapelon JY, Abou el Fadil F, Henry L, Theillere Y, Ponchon T,
Cathignol D: Extracorporeal ablation of liver tissue by high-intensity
focused ultrasound. Oncology 1993, 50:375–379.
4. Illing RO, Kennedy JE, Wu F, ter Haar GR, Protheroe AS, Friend PJ, Gleeson
FV, Cranston DW, Phillips RR, Middleton MR: The safety and feasibility of
extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of
liver and kidney tumours in a Western population. Br J Cancer 2005,
93:890–895.
5. Hwang JH, Crum LA: Current status of clinical high-intensity focused
ultrasound. Conf Proc IEEE Eng Med Biol Soc 2009, 2009:130–133.
6. Muto S, Yoshii T, Saito K, Kamiyama Y, Ide H, Horie S: Focal therapy with
high-intensity-focused ultrasound in the treatment of localized prostate
cancer. Jpn J Clin Oncol 2008, 38:192–199.
Sun et al. BMC Cancer 2014, 14:800 Page 11 of 11
http://www.biomedcentral.com/1471-2407/14/8007. Wu F, Wang ZB, Chen WZ, Zhu H, Bai J, Zou JZ, Li KQ, Jin CB, Xie FL, Su HB:
Extracorporeal high intensity focused ultrasound ablation in the
treatment of patients with large hepatocellular carcinoma. Ann Surg
Oncol 2004, 11:1061–1069.
8. Quesson B, Laurent C, Maclair G, de Senneville BD, Mougenot C, Ries M,
Carteret T, Rullier A, Moonen CT: Real-time volumetric MRI thermometry
of focused ultrasound ablation in vivo: a feasibility study in pig liver and
kidney. NMR Biomed 2011, 24:145–153.
9. Cline HE, Hynynen K, Hardy CJ, Watkins RD, Schenck JF, Jolesz FA: MR
temperature mapping of focused ultrasound surgery. Magn Reson Med
1994, 31:628–636.
10. Hynynen K, Darkazanli A, Unger E, Schenck JF: MRI-guided noninvasive
ultrasound surgery. Med Phys 1993, 20:107–115.
11. Huisman M, van den Bosch MA: MR-guided high-intensity focused
ultrasound for noninvasive cancer treatment. Cancer Imaging 2011,
11:S161–S166.
12. Hokland SL, Pedersen M, Salomir R, Quesson B, Stodkilde-Jorgensen H,
Moonen CT: MRI-guided focused ultrasound: methodology and applications.
IEEE Trans Med Imaging 2006, 25:723–731.
13. Jolesz FA, Hynynen K, McDannold N, Freundlich D, Kopelman D:
Noninvasive thermal ablation of hepatocellular carcinoma by using
magnetic resonance imaging-guided focused ultrasound.
Gastroenterology 2004, 127:S242–S247.
14. Gianfelice D, Khiat A, Amara M, Belblidia A, Boulanger Y: MR imaging-guided
focused US ablation of breast cancer: histopathologic assessment of
effectiveness– initial experience. Radiology 2003, 227:849–855.
15. Hesley GK, Gorny KR, Henrichsen TL, Woodrum DA, Brown DL: A clinical review
of focused ultrasound ablation with magnetic resonance guidance: an
option for treating uterine fibroids. Ultrasound Q 2008, 24:131–139.
16. Hindley J, Gedroyc WM, Regan L, Stewart E, Tempany C, Hynyen K,
McDannold N, Inbar Y, Itzchak Y, Rabinovici J, Kim HS, Geschwind JF, Hesley
G, Gostout B, Ehrenstein T, Hengst S, Sklair-Levy M, Shushan A, Jolesz F: MRI
guidance of focused ultrasound therapy of uterine fibroids: early results.
AJR Am J Roentgenol 2004, 183:1713–1719.
17. Cline HE, Hynynen K, Watkins RD, Adams WJ, Schenck JF, Ettinger RH,
Freund WR, Vetro JP, Jolesz FA: Focused US system for MR imaging-guided
tumor ablation. Radiology 1995, 194:731–737.
18. Kennedy JE: High-intensity focused ultrasound in the treatment of solid
tumours. Nat Rev Cancer 2005, 5:321–327.
19. Lynn JG, Zwemer RL, Chick AJ: The biological application of focused
ultrasonic waves. Science 1942, 96:119–120.
20. Tempany CM, McDannold NJ, Hynynen K, Jolesz FA: Focused ultrasound
surgery in oncology: overview and principles. Radiology 2011, 259:39–56.
21. Harari PM, Hynynen KH, Roemer RB, Anhalt DP, Shimm DS, Stea B, Cassady
JR: Development of scanned focussed ultrasound hyperthermia: clinical
response evaluation. Int J Radiat Oncol Biol Phys 1991, 21:831–840.
22. Mahmoudi M, Serpooshan V, Laurent S: Engineered nanoparticles for
biomolecular imaging. Nanoscale 2011, 3:3007–3026.
23. Dong W, Li Y, Niu D, Ma Z, Gu J, Chen Y, Zhao W, Liu X, Liu C, Shi J: Facile
synthesis of monodisperse superparamagnetic Fe3O4 Core@hybrid@Au
shell nanocomposite for bimodal imaging and photothermal therapy.
Adv Mater 2011, 23:5392–5397.
24. Laurent S, Bridot JL, Elst LV, Muller RN: Magnetic iron oxide nanoparticles
for biomedical applications. Future Med Chem 2010, 2:427–449.
25. Lee JH, Schneider B, Jordan EK, Liu W, Frank JA: Synthesis of complexable
fluorescent superparamagnetic iron oxide nanoparticles (FL SPIONs) and
cell labeling for clinical application. Adv Mater 2008, 20:2512–2516.
26. Frascione D, Diwoky C, Almer G, Opriessnig P, Vonach C, Gradauer K,
Leitinger G, Mangge H, Stollberger R, Prassl R: Ultrasmall
superparamagnetic iron oxide (USPIO)-based liposomes as magnetic
resonance imaging probes. Int J Nanomedicine 2012, 7:2349–2359.
27. Bulte JW, Hoekstra Y, Kamman RL, Magin RL, Webb AG, Briggs RW, Go KG,
Hulstaert CE, Miltenyi S, The TH: Specific MR imaging of human
lymphocytes by monoclonal antibody-guided dextran-magnetite
particles. Magn Reson Med 1992, 25:148–157.
28. Guo RM, Cao N, Zhang F, Wang YR, Wen XH, Shen J, Shuai XT: Controllable
labelling of stem cells with a novel superparamagnetic iron oxide-loaded
cationic nanovesicle for MR imaging. Eur Radiol 2012, 22:2328–2337.
29. Tong L, Zhao M, Zhu S, Chen J: Synthesis and application of
superparamagnetic iron oxide nanoparticles in targeted therapy and
imaging of cancer. Front Med 2011, 5:379–387.30. Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, Bergemann C, Erhardt W,
Wagenpfeil S, Lubbe AS: Locoregional cancer treatment with magnetic
drug targeting. Cancer Res 2000, 60:6641–6648.
31. Luo W, Zhou X, Yu M, He G, Zheng X, Li Q, Liu Q, Han Z, Zhang J, Qian Y:
Ablation of high-intensity focused ultrasound assisted with Sonovue
on rabbit VX2 liver tumors: sequential findings with histopathology,
immunohistochemistry, and enzyme histochemistry. Ann Surg Oncol
2009, 16:2359–2368.
32. Yu T, Wang G, Hu K, Ma P, Bai J, Wang Z: A microbubble agent improves
the therapeutic efficiency of high intensity focused ultrasound: a rabbit
kidney study. Urol Res 2004, 32:14–19.
33. Rapoport N, Nam KH, Gupta R, Gao Z, Mohan P, Payne A, Todd N, Liu X,
Kim T, Shea J, Scaife C, Parker DL, Jeong EK, Kennedy AM: Ultrasound-
mediated tumor imaging and nanotherapy using drug loaded, block
copolymer stabilized perfluorocarbon nanoemulsions. J Control Release
2011, 153:4–15.
34. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK:
Regulation of transport pathways in tumor vessels: role of tumor type
and microenvironment. Proc Natl Acad Sci 1998, 8:4607–4612.
35. Campbell RB: Tumor physiology and delivery of nanopharmaceuticals.
Anticancer Agents Med Chem 2006, 6:503–512.
36. Dibaji SAR, Al-Rjoub MF, Myers MR, Banerjee RK: Enhanced heat transfer
and thermal dose using magnetic nanoparticles during HIFU thermal
ablation-an in-vitro study. J Nanotechnol Eng Med 2014, 4(041003):1–8.
doi:10.1186/1471-2407-14-800
Cite this article as: Sun et al.: Evaluation of superparamagnetic iron
oxide-polymer composite microcapsules for magnetic resonance-guided
high-intensity focused ultrasound cancer surgery. BMC Cancer
2014 14:800.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
